Loading patent…
AssigneeKind Pharmaceutical
InventorsQi ZHU, Yusha ZHU, Ping DU, Dong LIU, Pengyang YU, Danyan GU, Wenjuan WANG, Peipei ZHU, Min XIONG, Shaojiang DENG
Estimating the term…
Disclosed are a long-acting oral pharmaceutical comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and use thereof. Specifically, disclosed is a long-acting oral pharmaceutical formulation comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients. The long-acting oral pharmaceutical formulation is suitable for administration at intervals of once every one week or longer, making it suitable for long-term administration in the treatment of chronic anemia.
A long-acting oral pharmaceutical preparation, comprising a hypoxia inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients, wherein the long-acting oral pharmaceutical preparation is suitable for administration at a dosing interval of once weekly or longer.
A pharmaceutical kit, comprising a packaging container, a medication instruction, and a pharmaceutical preparation contained within the packaging container, wherein the pharmaceutical preparation comprises a hypoxia inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients, and the medication instruction contains information indicating that the pharmaceutical preparation is suitable for oral administration at a dosing interval of once weekly or longer.
A method for treating chronic anemia, comprising:
Dependencies are inferred from the claim text.